From chemistry-request[ AT ]server.ccl.net Thu Sep 9 01:43:54 1999 Received: from ccl.net (atlantis.ccl.net [192.148.249.4]) by server.ccl.net (8.8.7/8.8.7) with ESMTP id BAA17532 for ; Thu, 9 Sep 1999 01:43:49 -0400 Received: from basfegw1.basf-ag.de (basfegw1.basf-ag.de [141.6.1.21]) by ccl.net (8.8.6/8.8.6/OSC 1.1) with ESMTP id BAA02000 for ; Thu, 9 Sep 1999 01:39:32 -0400 (EDT) From: hugo.kubinyi#* at *#basf-ag.de Received: from basfigw1.fw.basf-ag.de (actually host dmz-igw1) by basfegw1.basf-ag.de with SMTP (XT-PP) with ESMTP; Thu, 9 Sep 1999 07:39:30 +0200 Received: from pluto1.zx.basf-ag.de by basfigw1.fw.basf-ag.de with SMTP (XT-PP); Thu, 9 Sep 1999 07:39:29 +0200 Received: by pluto1.zx.basf-ag.de(Lotus SMTP MTA v4.6.3 (778.2 1-4-1999)) id C12567E7.001EF870 ; Thu, 9 Sep 1999 07:38:16 +0200 X-Lotus-FromDomain: BASF-AG To: CCL , QSAR Society , Roger Lahana Message-ID: Date: Thu, 9 Sep 1999 07:39:21 +0200 Subject: Drug-like inactive molecules Mime-Version: 1.0 Content-type: text/plain; charset=us-ascii Content-Disposition: inline Dear Roger, from my point of view, the "most drug-like" inactive molecules should be the molecules listed in the WDI or in similar drug collections. There should be at least one or several biological target/s for every member at which the respective "drug" is inactive. Another good source might be the literature. There are thousands of publications where active, less active and even inactive analogs are listed with their quantitative data. So what? Best regards Hugo